Mainz Biomed B.V.

NASDAQ:MYNZ   3:08:56 PM EDT
8.77
-0.06 (-0.66%)
Earnings Announcements

Mainz Biomed Announces U.S. Extension Of Colofuture Study To Evaluate Integration Of Novel MRNA Biomarkers Into Coloalert

Published: 11/15/2022 14:58 GMT
Mainz Biomed B.V. (MYNZ) - Mainz Biomed Announces U.S. Extension of Colofuture Study to Evaluate Integration of Novel Mrna Biomarkers Into Coloalert.
Mainz Biomed NV - Eaarly Detect Expected to Complete Enrollment in Q1 2023 With Results in 1h 2023.
Mainz Biomed - Will Determine If Any Biomarkers Are Eligible for Inclusion in Company's U.S. Pivotal Study, Which is on Track to Initiate in Q4 2022.